Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00595686 |
Recruitment Status :
Completed
First Posted : January 16, 2008
Last Update Posted : May 17, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hematologic Neoplasms | Drug: SNX-5422 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 25 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | May 2010 |
Actual Study Completion Date : | May 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: Single Arm |
Drug: SNX-5422
dose escalated; tablets every other day; undetermined duration until disease progression |
- adverse events and other safety assessments [ Time Frame: continuous ]
- disease response specific to the hematological malignancy [ Time Frame: after every 2 cycles ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- >18 years old
- Karnofsky performance status > 60
- confirmed hematological malignancy
- refractory to available therapy or for which no therapy is available
- adequate hepatic, renal and hematological function
Exclusion Criteria:
- CNS malignancy
- at risk for prolonged QT interval
- significant GI/liver disease
- other serious concurrent illness or medical condition
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00595686
United States, Georgia | |
Pfizer Investigational Site | |
Augusta, Georgia, United States, 30912 | |
United States, North Carolina | |
Pfizer Investigational Site | |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Pittsburgh, Pennsylvania, United States, 15232 | |
United States, Tennessee | |
Pfizer Investigational Site | |
Nashville, Tennessee, United States, 37232 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
ClinicalTrials.gov Identifier: | NCT00595686 |
Other Study ID Numbers: |
B1311002 SNX-5422-CLN1-002 |
First Posted: | January 16, 2008 Key Record Dates |
Last Update Posted: | May 17, 2012 |
Last Verified: | May 2012 |
Hematologic Malignancies Hsp90 Hematologic Malignancy |
Neoplasms Hematologic Neoplasms Neoplasms by Site Hematologic Diseases |